CMV DNA e MRNA Pp67 nel monitoraggio del paziente sottoposto a trapianto di midollo osseo

Abstract

Primary infection of immunocompetent individuals does not lead to complication, but CMV is a major clinical problem in transplant recipients.Thus, it is important to use sensitive and specific diagnostic techniques to rapidly and accurately detect CMV infection and identify patients at risk of developing CMV disease. In the present study, CMV infection after bone marrow transplantation was monitored by two molecular biology assays: COBAS AMPLICOR CMV MONITOR and NUCLISENS CMV m-RNA pp67. CMV m-RNApp67 assay was found to show positivity later than CMV-DNA MONITOR. The increment of number of copies/ml agreed with the clinical symptoms of CMV infection. The quantitative results of the CMV MONTOR assay was more helpfull to select an antiviral strategy than the qualitative results of NUCLISENS m-RNA pp67 assay.